Kaplan-Meier curves of progression-free survival (PFS) for <sup>62</sup>Cu-ATSM PET (a) and <sup>18</sup>F-FDG PET (b) in patients with HNC. Tetsuya Tsujikawa Satoko Asahi Myungmi Oh Yoshitaka Sato Norihiko Narita Akira Makino Tetsuya Mori Yasushi Kiyono Tatsuro Tsuchida Hirohiko Kimura Shigeharu Fujieda Hidehiko Okazawa 10.1371/journal.pone.0155635.g003 https://plos.figshare.com/articles/figure/Kaplan-Meier_curves_of_progression-free_survival_PFS_for_sup_62_sup_Cu-ATSM_PET_a_and_sup_18_sup_F-FDG_PET_b_in_patients_with_HNC_/3939063 <p>Two groups of high (dotted lines) and low (solid lines) tracer accumulation were determined by each cut-off value of the tumor-to-muscle ratios (TMR<sub>ATSM</sub> and TMR<sub>FDG</sub>). TMR<sub>ATSM</sub>, one of the intensity-based redox parameters, showed a significant difference in PFS between two groups (<i>p</i> = 0.03), whereas TMR<sub>FDG</sub>, one of the intensity-based metabolic parameters, did not (<i>p</i> = 0.15). The three-year PFS rate was 74% for patients with lower accumulation tumors (TMR<sub>ATSM</sub> ≤ 3.2) and 29% for those with over-reductive tumors (TMR<sub>ATSM</sub> > 3.2).</p> 2016-05-17 21:18:42 18 F-FDG threshold TMR ATSM SUV ATSM ROC analysis RTV CSS 18 F-FDG PET scans PSF 62 Cu-ATSM PET 18 F-FDG PET 62 Cu-ATSM Tumor Redox Status HNC patient outcomes TLR TLG tumor-to-muscle activity concentration ratios 62 Cu-ATSM PET Purpose Tumor redox MTV II PFS Conclusion Tumor redox parameters pretreatment 62 Cu-ATSM